Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Alnylam Pharmaceuticals, Inc. < Previous 1 2 3 4 5 Next > Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity October 31, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 October 30, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results October 17, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy October 16, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy October 09, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 September 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast TTR Investor Day September 26, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress August 30, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentations at Upcoming September Investor Conferences August 28, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Present Detailed Results from the HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress 2024 August 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Period Activity August 01, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing Second Quarter 2024 Financial Results July 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations June 24, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Issues 2023 Corporate Responsibility Report May 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity May 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results April 18, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension April 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session March 20, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease March 13, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives March 05, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentations at Upcoming March Investor Conferences February 27, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity February 15, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2023 Financial Results January 29, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association January 09, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates January 07, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Presentation at 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day December 13, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam to Webcast Virtual R&D Day December 06, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023 November 30, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY Alnylam Presents Positive Results from the KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development for the Treatment of Hypertension in Patients at High Cardiovascular Risk November 11, 2023 From Alnylam Pharmaceuticals, Inc. Via Business Wire Tickers ALNY < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
